These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6673058)

  • 21. Bioavailability of prednisolone in asthmatic patients with a poor response to steroid treatment.
    Mortimer O; Grettve L; Lindström B; Lönnerholm G; Zetterström O
    Eur J Respir Dis; 1987 Nov; 71(5):372-9. PubMed ID: 3443161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of portasystemic anastomoses in childhood on propranolol pharmacokinetics].
    Cario WR; Glende M; Lampe D; Buchali K; Bürger K; Grossmann P; Huth M; Rüstow B; Zimmermann HB
    Schweiz Med Wochenschr; 1981 Jul; 111(29):1088-93. PubMed ID: 7268362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.
    Dove AM; Szefler SJ; Hill MR; Jusko WJ; Larsen GL; Accurso FJ
    J Pediatr; 1992 May; 120(5):789-94. PubMed ID: 1578318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of prednisolone in adrenal insufficiency ].
    von Papen C; Benker G; Hackenberg K; Reinwein D
    Klin Wochenschr; 1982 Jul; 60(13):681-6. PubMed ID: 7120877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.
    Madsbad S; Bjerregaard B; Henriksen JH; Juhl E; Kehlet H
    Gut; 1980 Jan; 21(1):52-6. PubMed ID: 7364321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC.
    Geier A; Gartung C; Dietrich CG; Wasmuth HE; Reinartz P; Matern S
    World J Gastroenterol; 2003 Dec; 9(12):2681-5. PubMed ID: 14669312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GC-MS: estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy.
    Shibasaki H; Nakayama H; Furuta T; Kasuya Y; Tsuchiya M; Soejima A; Yamada A; Nagasawa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):164-9. PubMed ID: 18387858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of plasma prednisolone in man.
    Wilson CG; Ssendagire R; May CS; Paterson JW
    Br J Clin Pharmacol; 1975 Aug; 2(4):321-5. PubMed ID: 1233991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propranolol disposition in chronic liver disease: a physiological approach.
    Branch RA; Shand DG
    Clin Pharmacokinet; 1976; 1(4):264-79. PubMed ID: 797499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of inflammatory bowel disease on absorption and disposition of prednisolone.
    Milsap RL; George DE; Szefler SJ; Murray KA; Lebenthal E; Jusko WJ
    Dig Dis Sci; 1983 Feb; 28(2):161-8. PubMed ID: 6825536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.
    Szefler SJ; Ebling WF; Georgitis JW; Jusko WJ
    Eur J Clin Pharmacol; 1986; 30(3):323-9. PubMed ID: 3732369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of altered prednisolone kinetics in patients with the nephrotic syndrome and in women taking oral contraceptive steroids on human mixed lymphocyte cultures.
    Frey BM; Frey FJ
    J Clin Endocrinol Metab; 1985 Feb; 60(2):361-9. PubMed ID: 3155524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.
    Li C; Kim M; Choi JS
    Arch Pharm Res; 2010 Sep; 33(9):1395-400. PubMed ID: 20945138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.
    Uribe M; Schalm SW; Summerskill WH; Go VL
    Gut; 1978 Dec; 19(12):1131-5. PubMed ID: 744499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.
    Davis M; Williams R; Chakraborty J; English J; Marks V; Ideo G; Tempini S
    Br J Clin Pharmacol; 1978 Jun; 5(6):501-5. PubMed ID: 656293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin.
    Bergrem H; Refvem OK
    Proc Eur Dial Transplant Assoc; 1983; 19():552-7. PubMed ID: 6878255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.
    Frey FJ; Rüegsegger MK; Frey BM
    Br J Clin Pharmacol; 1986 Feb; 21(2):183-9. PubMed ID: 3954934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.
    Gambertoglio JG; Amend WJ; Benet LZ
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):1-52. PubMed ID: 6991663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different prednisolone pharmacokinetics in Cushingoid and non-Cushingoid kidney transplant patients.
    Bergrem H; Jervell J; Flatmark A
    Proc Eur Dial Transplant Assoc; 1983; 20():286-90. PubMed ID: 6361740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of liver diseases on bioavailability and clearance of drugs].
    Paumgartner G
    Internist (Berl); 1980 Dec; 21(12):718-23. PubMed ID: 7009473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.